This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
F-star Therapeutics Crecimiento futuro
Future controles de criterios 2/6
Información clave
9.7%
Tasa de crecimiento de los beneficios
21.7%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 24.0% |
| Tasa de crecimiento de los ingresos | 59.0% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 09 Mar 2023 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
F-star Therapeutics: Running Into A National Security Roadblock
Sep 22F-star Therapeutics falls on extended CFIUS review for Sino-Biopharma sale
Sep 15F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon
Jul 29F-star enters license deal with Takeda for a cancer immune therapy antibody
Jul 20Need To Know: Analysts Are Much More Bullish On F-star Therapeutics, Inc. (NASDAQ:FSTX) Revenues
May 18
US$26.50: That's What Analysts Think F-star Therapeutics, Inc. (NASDAQ:FSTX) Is Worth After Its Latest Results
Mar 17These Analysts Just Made An Incredible Downgrade To Their F-star Therapeutics, Inc. (NASDAQ:FSTX) EPS Forecasts
Mar 16F-star Therapeutics: Best-In-Class Tetravalent Bispecific Antibody Technology In Cancers
Jan 27F-star Therapeutics under pressure on pricing $65M stock offering
May 07Here's What F-star Therapeutics, Inc.'s (NASDAQ:FSTX) Shareholder Ownership Structure Looks Like
Mar 17Merck KGaA discloses 5.4% stake in F-star Therapeutics
Feb 02Dosing underway in early-stage study of F-star's FS120 in cancer
Dec 03Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2025 | 10 | -80 | N/A | -75 | 1 |
| 12/31/2024 | 10 | -68 | N/A | -64 | 1 |
| 12/31/2023 | 3 | -73 | N/A | -61 | 2 |
| 12/31/2022 | 4 | -56 | N/A | -51 | 2 |
| 9/30/2022 | 21 | -45 | -38 | -38 | N/A |
| 6/30/2022 | 21 | -37 | -32 | -32 | N/A |
| 3/31/2022 | 21 | -34 | -25 | -25 | N/A |
| 12/31/2021 | 21 | -31 | -28 | -27 | N/A |
| 9/30/2021 | 4 | -45 | -51 | -50 | N/A |
| 6/30/2021 | 12 | -37 | -38 | -37 | N/A |
| 3/31/2021 | 13 | -28 | -30 | -29 | N/A |
| 12/31/2020 | 11 | -26 | -17 | -16 | N/A |
| 9/30/2020 | 13 | -23 | -9 | -9 | N/A |
| 6/30/2020 | 5 | -25 | -20 | -20 | N/A |
| 3/31/2020 | 17 | -24 | -21 | -21 | N/A |
| 12/31/2019 | 28 | -23 | -22 | -22 | N/A |
| 12/31/2018 | 38 | 17 | 3 | 16 | N/A |
| 12/31/2017 | 15 | 5 | 5 | 18 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: FSTX is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: FSTX is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: FSTX is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: FSTX's revenue (59% per year) is forecast to grow faster than the US market (6.9% per year).
Ingresos de alto crecimiento: FSTX's revenue (59% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if FSTX's Return on Equity is forecast to be high in 3 years time